Retatrutide

Retatrutide is an investigational triple-receptor agonist peptide (targets GLP-1, GIP, and glucagon receptors) under development for obesity and type 2 diabetes^[1][2]. Phase 2 trials demonstrated remarkable weight-loss efficacy, with patients losing up to 24% of body weight at 48 weeks on higher doses^[3][4]. This educational protocol presents a once-weekly subcutaneous approach with gradual titration to minimize gastrointestinal side effects.

• Reconstitute: Add 2.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
• Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
• Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks.280